You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.
Instead of measuring metabolites directly, the researchers used mass cytometry and multiplexed ion beam imaging to measure proteins involved in metabolic regulation.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
In Q2 the firm filed for FDA Emergency Use Authorization for its saliva-based Advanta Sx SARS-CoV-2 RT-PCR assay as it continued its pivot to COVID-19 markets.
The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.
Fluidigm's Helios mass cytometer and Hyperion imaging system will be bundled with De Novo's FCS Express 7 Flow software for suspension data analysis.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The study is enrolling up to 2,000 patients at 10 US medical centers and using omics approaches to profile their immune response over the course of a year.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.